Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000686469 | SCV000813988 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2024-01-13 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 1343 of the ALK protein (p.Thr1343Ile). This variant is present in population databases (rs753763148, gnomAD 0.03%). This missense change has been observed in individual(s) with high grade glioma (PMID: 26580448). ClinVar contains an entry for this variant (Variation ID: 566608). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV001021707 | SCV001183355 | likely benign | Hereditary cancer-predisposing syndrome | 2021-12-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| Baylor Genetics | RCV000686469 | SCV004199229 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2023-09-19 | criteria provided, single submitter | clinical testing |